John S. Kovach, MD founded Lixte and has been its sole administrative officer. Dr. Kovach has directed leading National Cancer Institute–designated Comprehensive Cancer Centers at Mayo Clinic, Rochester, Minnesota and City of Hope National Medical Center, Los Angeles, California. He has extensive experience in medical oncology, anti-cancer drug pharmacology, and in applied medical research, particularly, the early evaluation of new anti-cancer drugs and the development and management of multi-disciplinary highly productive cancer research teams. Dr. Kovach, in consultation with Lixte’s advisors and board, is responsible for the selection and prioritization of the scientific directions and goals of Lixte. Philip F. Palmedo, PhD is a physicist, entrepreneur, and corporate manager. He founded and served as Chairman of the International Resources Group (IRG), an international consultancy in energy, natural resources and economic development. IRG was bought by L3 Communications in 2008. Dr. Palmedo designed and was the first President of the Long Island Research Institute formed by Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and Stony Brook University to facilitate the commercialization of technologies. In 1988 Dr. Palmedo joined in the formation of Kepler Financial Management, Ltd., a quantitative financial research and trading company. He was President and Managing Director until 1991 when Renaissance Technologies Corporation acquired the company. In 2005 he co-founded the quantitative hedge fund, Kepler Asset Management, and serves as Chairman and Managing Director of the firm. Dr. Palmedo served on the boards of Asset Management Advisors, the Teton Trust Company and C-Quest Capital, and is currently a member of the Board of Directors of EHR Investments and the Gyrodyne Corporation of America. He also served on the Board of Trustees of Williams College and of the Stony Brook (University) Foundation and chaired the Foundation’s Investment Committee. Robert B. Royds, M.B, B.S., M.R.C.P. is Chair of the Board and Medical Director of Theradex Systems, Inc., a leading clinical research organization, with research bases in Europe, Australia, and Japan. Dr. Royds is responsible for the scientific affairs of the company. Trained in internal medicine and pharmacology, he has extensive experience in all stages of clinical drug development process. Before founding Theradex®, Dr. Royds was Senior Research Physician at Hoffmann-La Roche, Inc., and Associate Director for Clinical Pharmacology International at Merck, Sharp, and Dohme Research Laboratories. He has been a consultant/advisor to the National Institute of Child Health and Development and the National Cancer Institute on issues of clinical trial design and international standardization of data sets of clinical trials of new investigational anti-cancer agents. Dr. Royds has served as the physician-monitor for the Clinical Trials Monitoring Service of the National Cancer Institute since 1979, and has been the Principal Investigator for this contract since 1982. Mel Sorensen, MD is Director, President and CEO of Ascenta Therapeutics, a private clinical-stage cancer drug development company located in the Greater Philadelphia area. Dr. Sorensen also serves as Chairman of the Board of Therasis, Inc., a cancer systems biology company in New York City. He is a highly experienced leader and administrator in cancer therapeutics and cancer drug development and is a frequent speaker on the strategic and operational aspects of cancer drug development. He also is an advisor to the Biomarkers Consortium of the National Institutes of Health. At Ascenta, Dr. Sorensen raised nearly $100M in private financing, advanced several preclinical agents into clinical development and in June 2010 closed a $398 Million deal with sanofi-aventis for one of Ascenta’s three programs. Dr. Sorensen was Chairman of Ascenta Shanghai, a wholly-owned subsidiary in Shanghai, China from 2005-2009, until it was divested in 2009. Dr. Sorensen has dedicated his career to clinical cancer research since completing his oncology fellowship at the Mayo Clinic in 1988 and has spent approximately seven years each in patient care, in academia (at the National Cancer Institute), in leadership positions of clinical cancer research in the pharmaceutical industry (Bayer & GlaxoSmithKline), and in biotech.